The regulatory oversight of biologicals in Malaysia is established by the National Pharmaceutical Control Bureau (NPCB), Ministry of Health. At the agency, the Section on Biotechnology Product Registration exercises the marketing authorization function as the National Regulatory Authority (NRA). This paper provides an overview of the organization, regulatory expectations and current practices of the evaluation of biologicals in Malaysia. Recent developments in the regulation of biologicals, focusing on biosimilars, are also presented. Because of the rapid pace of science and evolving regulatory controls, collaboration with local and international stakeholders is key to enhancing the safety and availability of biologicals/biosimilars in a cost-effective manner while meeting important medical needs. As resources for capacity building are not always at our disposal, we actively explore partnerships with our international counterparts who face common regulatory challenges.
CITATION STYLE
Abas, A., & Khoo, Y. S. K. (2014). Regulation of biologicals in Malaysia. GaBI Journal, 3(4), 193–198. https://doi.org/10.5639/gabij.2014.0304.044
Mendeley helps you to discover research relevant for your work.